Effects of CACNA1C, eNOS, and RGS2 gene polymorphisms on the antihypertensive response of dihydropyridine calcium channel blockers in patients with essential hypertension.

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-PRNC-12002690

Enrollment

Unknown

Registered

2012-11-19

Start date

2011-09-11

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

essential hypertension

Interventions

antihypertension response:antihypertension drugs

Eligibility

Sex/Gender

All

Age

41 Years to 74 Years

Inclusion criteria

Inclusion criteria: Men or women; diagnosed with EH, confirmed with two or more times BPs, SBP>140mm Hg or DBP >90mm Hg; never received antihypertensive therapy before; with entire 6 weeks of clinical follow up date and blood sample.

Exclusion criteria

Exclusion criteria: Secondary hypertension, heart failure, myocardial infarction, stroke, renal or liver dysfunction, malignant tumor or taking any medication that would further affect BP during CCBs monotherapy.

Design outcomes

Primary

Measure	Time frame
blood pressure;	—

Countries

China

Contacts

Public ContactWei Zhang

yjsd2003@163.com+86 0731 8480-5380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026